新股消息 | 麓鹏制药递表港交所 核心产品LP-168为全球首个且唯一的“共价兼非共价”双重BTK抑制剂
Last Update:
2 11 月, 2025
Please share this article if you like it!
Our site uses cookies. By using this site, you agree to the Privacy Policy and Terms of Use.